Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins.
We have described recently the construction of a defective vaccinia virus (VV) lacking the essential D4R open reading frame and have shown furthermore the selection of a complementing cell line providing the essential D4R gene product. The D4R gene belongs to the group of early transcribed vaccinia genes preventing a virus defective in D4R from entering into the intermediate and late phase of replication under noncomplementing conditions. Here we show that this property, which is unique among the group of so called nonreplicating poxviruses, is helpful for the production of (secretable) recombinant human proteins. Recombinant VV based on a D4R-defective parental strain expressing cDNAs coding for the human blood coagulation factors VII and XI produced significantly more recombinant protein than the corresponding recombinants based on wild-type VV. Moreover, the complementing cell line RK-D4R-44.20 was a more effective production cell system for both vD4 and wild-type VV recombinants compared to wild-type RK-13 cells. Surprisingly, recombinant human factor VII was more efficiently produced with the defective vaccinia recombinant even under noncomplementing conditions, suggesting that persistence of the early phase of vaccinia replication in combination with a delayed host shutoff is advantageous for the overproduction of certain recombinant proteins using the VV expression system.
Himly
M
M
Baxter-Immuno AG Biomedical Research Center, Uferstrasse 15, Orth/Donau, A-2304, Austria. martin.himly@sbg.ac.at
Pfleiderer
M
M
Holzer
G
G
Fischer
U
U
Hannak
E
E
Falkner
F G
FG
Dorner
F
F
D000818:Animals; D002460:Cell Line; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D045647:DNA Glycosylases; D018076:DNA, Complementary / Q000235:genetics; D003673:Defective Viruses / Q000235:genetics* / Q000502:physiology; D005167:Factor VII / Q000096:biosynthesis* / Q000235:genetics / Q000302:isolation & purification; D005172:Factor XI / Q000096:biosynthesis* / Q000235:genetics / Q000302:isolation & purification; D005816:Genetic Complementation Test; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D009699:N-Glycosyl Hydrolases / Q000172:deficiency / Q000235:genetics; D016366:Open Reading Frames; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000302:isolation & purification; D012449:Safety; D051981:Uracil-DNA Glycosidase; D014616:Vaccinia virus / Q000235:genetics* / Q000502:physiology; D014764:Viral Proteins / Q000235:genetics; D014779:Virus Replication
D018076:DNA, Complementary; D011993:Recombinant Fusion Proteins; D014764:Viral Proteins; D005167:Factor VII; D005172:Factor XI; D045647:DNA Glycosylases; D009699:N-Glycosyl Hydrolases; D051981:Uracil-DNA Glycosidase